Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Supports P&T decisions on late-phase agents; extends synthesized trial data access for formulary review.
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. Subscribers to The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The January 2012 monograph topics are on clobazam, ruxolitinib, bupivacaine liposome injection suspension, ivacaftor, and teriflunomide. The DUE/MUE is on clobazam.
No takes yet. Share an insight, caveat, or question.
Dennis et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: